Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.58 |
| ▸ | ERN1 | O75460 | 3/20 | 0.56 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.51 |
| ▸ | TYR | P14679 | 1/20 | 0.51 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.47 |
| ▸ | JUN | P05412 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.46 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.46 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4599003 | 0.86 | TUBB1 (0.54) | ALDH1A1ERN1TRIM24TYRTRIM33 | |
| SCHEMBL172939 | 0.85 | ALDH1A1 (0.71) | ALDH1A1ERN1TRIM24TYRTRIM33 | |
| SCHEMBL29392394 | 0.85 | ALDH1A1 (0.71) | ALDH1A1ERN1TRIM24TYRTRIM33 | |
| SCHEMBL16112011 | 0.77 | ALDH1A1 (0.61) | ALDH1A1ERN1TRIM24TYRTRIM33 | |
| SCHEMBL27945949 | 0.77 | ALDH1A1 (0.56) | ALDH1A1ERN1TRIM24TYRTRIM33 | |
| SCHEMBL7591800 | 0.77 | ERN1 (0.59) | ALDH1A1ERN1TRIM24TYRTRIM33 | |
| SCHEMBL20488634 | 0.77 | KDM4E (0.59) | ALDH1A1ERN1TRIM24TYRTRIM33 | |
| SCHEMBL17919655 | 0.77 | ALDH1A1 (0.56) | ALDH1A1ERN1TRIM24TYRTRIM33 | |
| SCHEMBL29957021 | 0.77 | ALDH1A1 (0.70) | ALDH1A1ERN1TRIM24TYRTRIM33 | |
| SCHEMBL12672585 | 0.77 | ALDH1A1 (0.70) | ALDH1A1ERN1TRIM24TYRTRIM33 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10900941-B2 | Determining stereoisomeric excess, concentration and absolute configuration | GEORGETOWN UNIVERSITY (US) | 2021-01-26 | — | — | US | claimed |
| US-20180364206-A1 | DETERMINING STEREOISOMERIC EXCESS, CONCENTRATION AND ABSOLUTE CONFIGURATION | GEORGETOWN UNIVERSITY | 2018-12-20 | — | — | US | claimed |
| US-10900941-B2 | Determining stereoisomeric excess, concentration and absolute configuration | GEORGETOWN UNIVERSITY (US) | 2021-01-26 | — | — | US | disclosed |
| US-10788471-B2 | Determining stereoisomeric excess, concentration and absolute configuration | GEORGETOWN UNIVERSITY (US) | 2020-09-29 | — | — | US | disclosed |
| US-20180364206-A1 | DETERMINING STEREOISOMERIC EXCESS, CONCENTRATION AND ABSOLUTE CONFIGURATION | GEORGETOWN UNIVERSITY | 2018-12-20 | — | — | US | disclosed |
| US-20180292370-A1 | DETERMINING STEREOISOMERIC EXCESS, CONCENTRATION AND ABSOLUTE CONFIGURATION | UNIV GEORGETOWN (US) | 2018-10-11 | — | — | US | disclosed |
| US-10012627-B2 | Determining stereoisomeric excess, concentration and absolute configuration | GEORGETOWN UNIVERSITY (US) | 2018-07-03 | — | — | US | disclosed |
| EP-2099804-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20160011156-A1 | DETERMINING STEREOISOMERIC EXCESS, CONCENTRATION AND ABSOLUTE CONFIGURATION | GEORGETOWN UNIVERSITY | 2016-01-14 | — | — | US | disclosed |
| EP-2518073-B1 | Compounds for the treatment of Hepatitis C | BRISTOL MYERS SQUIBB CO (US) | 2015-08-26 | — | — | EP | disclosed |
| EP-2118109-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2014-11-26 | — | — | EP | disclosed |
| US-6849619-B2 | Substituted pyridoindoles as serotonin agonists and antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-02-01 | — | — | US | disclosed |
| US-20040186094-A1 | Substituted pyridoindoles as serotonin agonists and antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-09-23 | — | — | US | disclosed |
| US-6713471-B1 | SUCH AS TERT-BUTYL-1-METHYL-6,7,9,12-TETRAHYDRO-5H-PYRIDO-(4,3-B)(1,4) THIAZEPINO(2,3,4-HI)INDOLE-11(10H)-CARBOXYLATE; SEROTONIN AGONISTS AND ANTAGONISTS; CENTRAL NERVOUS SYSTEM DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-30 | — | — | US | disclosed |
| US-6699852-B2 | ANTISEROTONIN AGENTS; CENTRAL NERVOUS SYSTEM DISORDERS; ANTIDEPRESSANTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-02 | — | — | US | disclosed |
| EP-1343791-A2 | SUBSTITUTED TETRACYCLIC PYRIDOINDOLES AS SEROTONIN AGONISTS AND ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-09-17 | — | — | EP | disclosed |
| US-20020173503-A1 | Substituted pyridoindoles as serotonin agonists and antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-11-21 | — | — | US | disclosed |
| WO-2002059129-A2 | SUBSTITUTED TETRACYCLIC PYRIDOINDOLES AS SEROTONIN AGONISTS AND ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
| EP-1192165-A2 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | Bristol-Myers Squibb Pharma Company (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2000077010-A2 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173503-A1 | Substituted pyridoindoles as serotonin agonists and antagonists | HTR1A, HTR1B, HTR7 | ALDH1A1 2258/4885ERN1 4009/4885TRIM24 4387/4885 |
| US-20040186094-A1 | Substituted pyridoindoles as serotonin agonists and antagonists | HTR1A, HTR1B, HTR7 | ALDH1A1 2258/4885ERN1 4009/4885TRIM24 4387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.